Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Inozyme Pharma, Inc. (INZY : NSDQ)

• Company Description    Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company's product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston, Massachusetts. Number of Employees: 67

• Price / Volume Information    Yesterday's Closing Price: $1.33 Daily Weekly Monthly 20 Day Moving Average: 1,030,700 shares Shares Outstanding: 64.56 (millions) Market Capitalization: $85.87 (millions) Beta: 1.35 52 Week High: $6.24 52 Week Low: $0.72 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 46.81% 42.27% 12 Week -1.48% 5.88% Year To Date -51.99% -49.85%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 321 SUMMER STREET SUITE 400 - BOSTON,MA 02210 USA ph: 857-330-4340 fax: - investorrelations@inozyme.com http://www.inozyme.com

• General Corporate Information    Officers Douglas A. Treco - Chief Executive Officer and Chairman Sanjay Subramanian - Chief Financial Officer Sarah Bhagat - Director Axel Bolte - Director Reinaldo Diaz - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45790W108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/24 Next Expected EPS Date: 05/06/25 Share - Related Items Shares Outstanding: 64.56 Most Recent Split Date: (:1) Beta: 1.35 Market Capitalization: $85.87 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.50 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 13.46% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.48 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -20.00% vs. Previous Quarter: -7.69% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - - 12/31/24 - -115.29 09/30/24 - -88.42 ROA 03/31/25 - - 12/31/24 - -68.09 09/30/24 - -57.02 Current Ratio 03/31/25 - - 12/31/24 - 3.56 09/30/24 - 7.68 Quick Ratio 03/31/25 - - 12/31/24 - 3.56 09/30/24 - 7.68 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - - 12/31/24 - 0.90 09/30/24 - 1.29 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - - 12/31/24 - 0.54 09/30/24 - 0.51 Debt-to-Capital 03/31/25 - - 12/31/24 - 35.23 09/30/24 - 33.69

Powered by Zacks Investment Research ©